Evidence map›Paper›PMID 41998453›Full record

ReviewWorld journal of microbiology & biotechnology2026

Klebsiella pneumoniae in the global AMR: resistance mechanisms and genomic adaptation.

A C Harini, Abhirami Krishnamoorthy Sundaresan, Jayapradha Ramakrishnan

Abstract readReview
PubMed Publisher
In one paragraph

Review in World journal of microbiology & biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

A C HariniActinomycetes Bioprospecting Lab, Centre for Research in Infectious Diseases (CRID), School of Chemical and Biotechnology (SCBT), SASTRA Deemed University, Tirumalaisamudram, Thanjavur, 613401, Tamil Nadu, India.
Abhirami Krishnamoorthy SundaresanActinomycetes Bioprospecting Lab, Centre for Research in Infectious Diseases (CRID), School of Chemical and Biotechnology (SCBT), SASTRA Deemed University, Tirumalaisamudram, Thanjavur, 613401, Tamil Nadu, India.
Jayapradha RamakrishnanActinomycetes Bioprospecting Lab, Centre for Research in Infectious Diseases (CRID), School of Chemical and Biotechnology (SCBT), SASTRA Deemed University, Tirumalaisamudram, Thanjavur, 613401, Tamil Nadu, India. antibioticbiology@gmail.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Antimicrobial Resistance (AMR) represents a defining crisis of modern healthcare, severely limiting therapeutic options and driving a global increase in clinical mortality. Central to this crisis is Klebsiella pneumoniae, a ubiquitous gut commensal that has evolved into a formidable opportunistic pathogen through its remarkable ability to transition from a harmless organism to a hypervirulent, Multidrug-Resistant (MDR) threat. This review examines that pathogenic transition, emphasizing the dangerous convergence of virulence and resistance traits particularly within carbapenem-resistant lineages. The bacterium leverages an expansive “open” pangenome and immense genetic plasticity to act as a primary trafficker of AMR genes. We detail the molecular mechanisms underlying resistance across nearly all antibiotic classes including β-lactams, aminoglycosides, and last-resort polymyxins driven by enzymatic degradation, target modification, and sophisticated efflux systems. Beyond clinical antibiotic pressure, the review explores how non-antibiotic drivers, such as environmental stressors, biocide exposure, and heavy metals, accelerate AMR evolution through cross-resistance and novel epigenetic adaptations. The rapid dissemination of these resistance determinants is facilitated by a robust toolkit of Horizontal Gene Transfer (HGT), including transposons, integrons, plasmid replicons, and bacteriophage-mediated transduction. Finally, this review evaluates the current therapeutic landscape, addressing the challenges of the drug development pipeline while highlighting emerging interventions such as novel β-lactam/β-lactamase inhibitor combinations, phage therapy, and anti-virulence strategies. Understanding this interplay between genomic evolution and ecological drivers is critical for designing a unified stewardship framework and effective interventions to curb the global AMR crisis.

Indexed as

Anti-Bacterial AgentsDrug Resistance, Multiple, BacterialKlebsiella InfectionsKlebsiella pneumoniaeAdaptation, Physiologicalbeta-LactamsGene Transfer, HorizontalGenome, BacterialHumansVirulenceAnti-Bacterial Agentsbeta-LactamsGenomic surveillanceKlebsiella pneumoniaeResistance mechanismsβ-lactam antibiotics

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.